Shaily Engineering Plastics reported a strong fiscal year with net profit rising 82.5% to ₹169.91 crore and revenue growing 25.91% to ₹990.67 crore. At its 46th AGM, shareholders approved an enabling resolution to raise up to ₹500 crore to support future capacity expansion and strategic opportunities. The company continues to shift its business mix toward high-margin healthcare products, which now account for 40% of its total revenue.
Shaily Engineering Plastics Reports Strong FY26 Growth and Approves Fundraising
FY26 Net Profit rose 82.5% to ₹169.91 crore; Revenue climbed 25.91% to ₹990.67 crore.
Reader Takeaway: Robust healthcare segment growth drives 35.8% ROCE, while new ₹500 crore fundraising authority supports future capacity scaling.
What just happened
Shaily Engineering Plastics held its 46th Annual General Meeting, where shareholders approved an enabling resolution to raise up to ₹500 crore. This move grants the company financial flexibility to pursue strategic investments and capacity expansion. The board also presented its FY26 performance, highlighting significant growth in both top and bottom lines as the firm pivots toward high-value engineering components.
Why this matters
The company’s strategic transition toward the healthcare sector is yielding results. Healthcare revenue surged 139% to ₹392.8 crore, now representing 40% of the total revenue mix, up from approximately 20% three years ago. This shift, combined with operational efficiencies, led to an EBITDA margin of 29% and a sharp 1,140 basis point expansion in Return on Capital Employed (ROCE) to 35.8%.
Business and Operational Strategy
Operationally, the company is scaling up. It recently commissioned 20,000 square meters of cleanroom space and added 21 injection-moulding machines to its facilities. The company successfully commercialized seven healthcare programmes, including its 'Neo' and 'Axiom' lines, and supplied 25 million medical devices. Looking ahead, it is expanding into consumer electronics and has signed a Korean partnership for conductive chip trays.
Outlook and Future Guidance
Management remains bullish, targeting consistent annual revenue growth of over 25% for the medium term. They expect the healthcare division to eventually contribute more than 50% of the company's total revenue. The focus remains on ensuring EBITDA growth outpaces revenue growth while sustaining high ROCE levels.
What to track next
Investors should monitor the utilization of the newly approved ₹500 crore fundraising mandate and the scheduled Q4 FY27 start of the conductive chip tray supply line to determine how quickly the company can scale these new revenue streams.